SEC Form 4 · accession 0001193125-26-318408
Kymera Therapeutics, Inc. · KYMR
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Terence Rooney
Officer — Chief Medical Officer
Period of report
Jul 27, 2026
Accepted (ET)
Jul 27, 2026 · 6:34 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001815442
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Jul 27, 2026 | A | 38,000 | $0.00 | A | 38,000 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F2 | $110.05 | Jul 27, 2026 | A | 76,000 | A | — | Jul 26, 2036 | Common Stock | 76,000 | 76,000 | D |
Explanation of responses
- F1Represents restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock upon vesting and settlement. The RSUs shall vest in four equal annualinstallments following July 27, 2026, subject to the reporting person's continued employment through each vesting date.
- F2Twenty-five percent (25%) of the shares underlying this stock option shall vest on July 27, 2027, with the remainder vesting in thirty-six (36) equal monthly installments thereafter, subject to the reporting person's continued employment through each vesting date.